Citations

Mayo Clinic

Showing 10 of 108599 citations.

Sodium–glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to haematology
Gangat, Naseema , Tefferi, Ayalew

Nephrology Dialysis Transplantation | July 20, 2023 | Volume: 38 | Issue: 12 | Pages: 2670-2672

10.1093/ndt/gfad171 | PMID 37468452 Get It

X-ray and MR Contrast Bearing Nanoparticles Enhance the Therapeutic Response of Image-Guided Radiation Therapy for Oral Cancer
Sharma, Gayatri , Kondelaji, Mir Hadi Razeghi, Sharma, Guru Prasad , Hansen, Christopher B. , Parchur, Abdul K. , Shafiee, Shayan , Fish, Brian L. , Bergom, Carmen , Paulson, E.S. , Hall, William A. , Himburg, Heather A. , Hansen, Christopher , Jagtap, Jaidip M, Joshi, Amit , Parchur, Abdul , Shafiee, Shayan , Himburg, Heather , Bergom, Carmen , Jagtap, Jaidip , Joshi, Amit

Technology in Cancer Research & Treatment | July 20, 2023 | Volume: 22 | Issue: No issue available | Pages: No page available

10.1177/15330338231189593 | PMID 37469184 Get It

Introduction Radiation therapy for head and neck squamous cell carcinoma is constrained by radiotoxicity to normal tissue. We demonstrate 100 nm theranostic nanoparticles for image-guided radiation therapy planning and enhancement in rat head and neck squamous cell carcinoma models. Methods PEG conjugated theranostic nanoparticles comprising of Au nanorods coated with Gadolinium oxide layers were tested for radiation therapy enhancement in 2D cultures of OSC-19-GFP-luc cells, and orthotopic tongue xenografts in male immunocompromised Salt sensitive or SS rats via both intratumoral and intravenous delivery. The radiation therapy enhancement mechanism was investigated. Results Theranostic nanoparticles demonstrated both X-ray/magnetic resonance contrast in a dose-dependent manner. Magnetic resonance images depicted optimal tumor-to-background uptake at 4 h post injection. Theranostic nanoparticle + Radiation treated rats experienced reduced tumor growth compared to controls, and reduction in lung metastasis. Conclusions Theranostic nanoparticles enable preprocedure radiotherapy planning, as well as enhance radiation treatment efficacy for head and neck tumors.
Severe eczema in Wiskott–Aldrich syndrome‐related disorder successfully treated with dupilumab
Alzahrani, Fatmah , Miller, Holly, Dupuy, Elizabeth , Sacco, Keith

Pediatric Dermatology | July 20, 2023 | Volume: 41 | Issue: 1 | Pages: 143-144

10.1111/pde.15397 | PMID 37469225 Get It

Abstract Treatment of severe eczema in patients with primary immunodeficiencies can be particularly challenging as there are no guidelines with regards to these conditions. Dupilumab is an interleukin (IL)‐4Rα antagonist that inhibits both IL‐4 and IL‐13 and is approved for the treatment of atopic dermatitis in pediatric patients. In this report, we describe a patient with a case of severe eczema in the context of Wiskott–Aldrich syndrome‐related disorder, who was successfully treated with dupilumab.
Dietary Patterns Are Not Associated With Disease Activity Among Patients With Inflammatory Conditions of the Pouch in a Prospective Cohort
Barnes, Edward L. , Beniwal‐Patel, Poonam , Deepak, Parakkal , Raffals, Laura H., Kayal, Maia , Dubinsky, Marla C. , Chang, Shannon, Higgins, Peter , Barr, Jennifer I, Anderson, Chelsea , Long, Millie D. , Herfarth, Hans , Herfarth, Hans H , Kayal, Maia , Deepak, Parakkal , Barnes, Edward L , Cross, Raymond K.

Crohn's & Colitis 360 | July 19, 2023 | Volume: 5 | Issue: 3 | Pages: No page available

10.1093/crocol/otad039 | PMID 37519405 Get It

Abstract Background Evidence-based recommendations regarding the influence of diet on inflammatory conditions of the pouch after restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA) are limited. Methods We analyzed dietary patterns at enrollment in a prospective registry of patients with 1 of 4 inflammatory conditions of the pouch (acute pouchitis, chronic antibiotic-dependent pouchitis, chronic antibiotic refractory pouchitis, and Crohn’s disease of the pouch). We analyzed dietary intake by disease activity at enrollment and then compared dietary patterns among patients who remained in remission throughout the 12-month follow-up to those patients who experienced a disease relapse. We also compared dietary patterns among patients with inflammatory conditions of the pouch to the United States Department of Agriculture (USDA) recommended daily goals. Results Among 308 patients, there were no differences in dietary patterns among patients with 1 of the 4 disease states at enrollment. Additionally, among the 102 patients in remission at baseline, there were no significant differences noted among patients who went on to experience a disease flare in the 12 months after enrollment compared to those patients who remained in remission. However, patients with inflammatory conditions of the pouch demonstrated decreased intake of several food groups and macronutrients including dairy, fruits, vegetables, whole grains, and fiber when compared to USDA recommendations. Conclusions In a prospective cohort, we demonstrated no impact of dietary patterns on disease activity. The relative deficiencies in several food groups and macronutrients among patients after IPAA indicate the potential role of targeted nutritional counseling in this population.
Susceptibility of nucleotide-binding oligomerization domain 2 mutations to Whipple’s disease
Williamson, Katrina Ann , Yun, Mark, Arment, Courtney, Patnaik, Asha , Chang, Tara W, Bledsoe, Adam C. , Sae-Tia, Sutthichai, Shah, Aditya , Williamson, Katrina A, Shah, Aditya S , Yao, Qingping , Yun, Mark, Koster, Matthew J. , Samuels, Jonathan , Davis, John M.

Rheumatology | July 19, 2023 | Volume: 63 | Issue: 5 | Pages: 1291-1296

10.1093/rheumatology/kead372 | PMID 37467078 Get It

Abstract Objectives Whipple’s disease (WD) results from infection of the bacteria Tropheryma whipplei (TW). This disease is characterized by macrophage infiltration of intestinal mucosa and primarily affects Caucasian males. Genetic studies of host susceptibility are scarce. Nucleotide-binding oligomerization domain containing protein 2 (NOD2) is an innate immune sensor, resides mainly in monocytes/macrophages and contributes to defence against infection and inflammatory regulation. NOD2 mutations are associated with autoinflammatory diseases. We report the association of NOD2 mutations with TW and WD for the first time. Methods A multicentre, retrospective study of three patients with WD was conducted. Patients received extensive multidisciplinary evaluations and were cared for by the authors. NOD2 and its association with infection and inflammation were schematically represented. Results All patients were Caucasian men and presented with years of autoinflammatory phenotypes, including recurrent fever, rash, inflammatory arthritis, gastrointestinal symptoms and elevated inflammatory markers. All patients underwent molecular testing using a gene panel for periodic fever syndromes and were identified to carry NOD2 mutations associated with NOD2-associated autoinflammatory disease. Despite initially negative gastrointestinal evaluations, repeat endoscopy with duodenal tissue biopsy ultimately confirmed WD. After initial ceftriaxone and maintenance with doxycycline and/or HCQ, symptoms were largely controlled, though mild relapses occurred in follow-up. Conclusion Both NOD2 and TW/WD are intensively involved in monocytes/macrophages. WD is regarded as a macrophage disease. NOD2 leucin-rich repeat–associated mutations in monocytes/macrophages cause functional impairment of these cells and consequently may make the host susceptible for TW infection and WD, especially in the setting of immunosuppression.
Stats on the desats: alarm fatigue and the implications for patient safety
Anderson, Hannah R, Borgen, Alex, Christnacht, Rebecca, Ng, Jenny, Weller, Joel G, Davison, Halley, O’Laughlin, Danielle , Disrud, Levi , Kashou, Anthony H. , Borgen, Alex C, Davison, Halley N, O'Laughlin, Danielle, Disrud, Levi , Noseworthy, Peter A. , Olson, Rachel

BMJ Open Quality | July 19, 2023 | Volume: 12 | Issue: 3 | Pages: e002262

10.1136/bmjoq-2023-002262 | PMID 37474134 Get It

Background Physiological monitoring systems, like Masimo, used during inpatient hospitalisation, offer a non-invasive approach to capture critical vital signs data. These systems trigger alarms when measurements deviate from preset parameters. However, often non-urgent or potentially false alarms contribute to ‘alarm fatigue,’ a form of sensory overload that can have adverse effects on both patients and healthcare staff. The Joint Commission, in 2021, announced a target to mitigate alarm fatigue-related fatalities through improved alarm management. Yet, no established guidelines are presently available. This study aims to address alarm fatigue at the Mayo Clinic to safeguard patient safety, curb staff burnout and improve the sensitivity of oxygen saturation monitoring to promptly detect emergencies. Methods A quality improvement project was conducted to combat minimise the false alarm burden, with data collected 2 months prior to intervention commencement. The project’s goal was to decrease the total alarm value by 20% from 55%–85% to 35%–75% within 2 months, leveraging quality improvement methodologies. Interventions February to April 2021, we implemented a two-pronged intervention: (1) instituting a protocol to evaluate patients’ continuous monitoring needs and discontinuing it when appropriate, and (2) introducing educational signage for patients and Mayo Clinic staff on monitoring best practices. Results Baseline averages of red alarms (158.6), manual snoozes (37.8) and self-resolves (120.7); the first postintervention phase showed reductions in red alarms (125.5), manual snoozes (17.8) and self-resolves (107.8). Second postintervention phase recorded 138 red alarms, 13 manual snoozes and 125 self-resolves. Baseline comparison demonstrated an average of 16.92% reduction of alarms among both interventions (p value: 0.25). Conclusion Simple interventions like education and communication techniques proved instrumental in lessening the alarm burden for patients and staff. The findings underscore the practical use and efficacy of these methods in any healthcare setting, thus contributing to mitigating the prevalent issue of alarm fatigue.
Etiology, morphology, and outcomes of adrenal calcifications in 540 adult patients—a retrospective single-center study
Kittithaworn, Annop , Dogra, Prerna , Rahimi, Leili , Sandooja, Rashi , Bancos, Irina , Bancos, Irina

European Journal of Endocrinology | July 19, 2023 | Volume: 189 | Issue: 1 | Pages: K1-K6

10.1093/ejendo/lvad093 | PMID 37474107 Get It

Abstract Sparse data are available on the etiology, morphology, clinical presentation, and outcomes of adrenal calcification. In this single-center retrospective study of 540 consecutive patients (median age 65 years, 45% women) with adrenal calcification on computed tomography (December 2017 to January 2021), most were discovered incidentally (472, 87%). The commonest etiology was idiopathic (389, 72%), followed by the adrenal tumor (113, 21%), hemorrhage (29, 5%), and infiltrative disease (7, 1%). Calcified adrenal tumors were predominantly benign (92, 81%) and primarily adenomas (63, 69%), whereas the most common calcified adrenal malignancy (16, 18%) was metastasis (12, 67%). Calcification (unilateral 94%, bilateral 6%) morphology varied from punctate (313, 58%) to coarse (165, 30%), linear/curvilinear (46, 9%), and rim-like (16, 3%). In summary, adrenal calcifications are usually incidentally discovered unilateral, punctate, or coarse lesions of unclear etiology. Most calcified adrenal tumors are benign and <20% malignant or pheochromocytomas.
Pearls and Pitfalls of Adaptive Optics Ophthalmoscopy in Inherited Retinal Diseases
Ashourizadeh, Helia , Fakhri, Maryam , Hassanpour, Kiana , Masoudi, Ali Akbar , Jalali, Sattar, Roshandel, Danial , Chen, Fred K. , Masoudi, Ali, Jalali, Sattar

Diagnostics | July 19, 2023 | Volume: 13 | Issue: 14 | Pages: 2413

10.3390/diagnostics13142413 | PMID 37510157 Get It

Adaptive optics (AO) retinal imaging enables individual photoreceptors to be visualized in the clinical setting. AO imaging can be a powerful clinical tool for detecting photoreceptor degeneration at a cellular level that might be overlooked through conventional structural assessments, such as spectral-domain optical coherence tomography (SD-OCT). Therefore, AO imaging has gained significant interest in the study of photoreceptor degeneration, one of the most common causes of inherited blindness. Growing evidence supports that AO imaging may be useful for diagnosing early-stage retinal dystrophy before it becomes apparent on fundus examination or conventional retinal imaging. In addition, serial AO imaging may detect structural disease progression in early-stage disease over a shorter period compared to SD-OCT. Although AO imaging is gaining popularity as a structural endpoint in clinical trials, the results should be interpreted with caution due to several pitfalls, including the lack of standardized imaging and image analysis protocols, frequent ocular comorbidities that affect image quality, and significant interindividual variation of normal values. Herein, we summarize the current state-of-the-art AO imaging and review its potential applications, limitations, and pitfalls in patients with inherited retinal diseases.
Targeted Alpha-Particle Therapy: A Review of Current Trials
Jang, Albert , Kendi, A. Tuba , Johnson, Geoffrey B. , Hálfdánarson, Þorvarður R. , Kendi, A Tuba , Halfdanarson, Thorvardur R , Johnson, Geoffrey B , Jang, Albert , Sartor, Oliver

International Journal of Molecular Sciences | July 19, 2023 | Volume: 24 | Issue: 14 | Pages: 11626

10.3390/ijms241411626 | PMID 37511386 Get It

Radiopharmaceuticals are rapidly developing as a field, with the successful use of targeted beta emitters in neuroendocrine tumors and prostate cancer serving as catalysts. Targeted alpha emitters are in current development for several potential oncologic indications. Herein, we review the three most prevalently studied conjugated/chelated alpha emitters (225actinium, 212lead, and 211astatine) and focus on contemporary clinical trials in an effort to more fully appreciate the breadth of the current evaluation. Phase I trials targeting multiple diseases are now underway, and at least one phase III trial (in selected neuroendocrine cancers) is currently in the initial stages of recruitment. Combination trials are now also emerging as alpha emitters are integrated with other therapies in an effort to create solutions for those with advanced cancers. Despite the promise of targeted alpha therapies, many challenges remain. These challenges include the development of reliable supply chains, the need for a better understanding of the relationships between administered dose and absorbed dose in both tissue and tumor and how that predicts outcomes, and the incomplete understanding of potential long-term deleterious effects of the alpha emitters. Progress on multiple fronts is necessary to bring the potential of targeted alpha therapies into the clinic.